BioDelivery Sciences International, Inc. is a pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. The company is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction. Its pain franchise currently consists of two products utilizing the patented BioErodible MucoAdhesive (BEMA) technology. ONSOLIS is approved in the United States, Canada, and the European Union for the management of breakthrough pain in opioid tolerant, adult patients with cancer. Its second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation with naloxone for the treatment of opioid dependence. BEMA Buprenorphine for chronic pain is licensed on a worldwide basis to Endo Pharmaceuticals. Its other products include BEMA Buprenorphine/Naloxone and BEMA Granisetron. The BEMA Buprenorphine/Naloxone used for the treatment of opioid dependency and BEMA Granisetron prevention of nausea and vomiting associated with cancer therapies. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC.
BioDelivery Sciences International, Inc.
801 Corporate Center Drive Suite 210
Raleigh, NC 27607
SIC Code: 2835